KR101399621B1 - 클로스트리듐 디피실리 관련 설사의 치료 방법 - Google Patents

클로스트리듐 디피실리 관련 설사의 치료 방법 Download PDF

Info

Publication number
KR101399621B1
KR101399621B1 KR1020087012193A KR20087012193A KR101399621B1 KR 101399621 B1 KR101399621 B1 KR 101399621B1 KR 1020087012193 A KR1020087012193 A KR 1020087012193A KR 20087012193 A KR20087012193 A KR 20087012193A KR 101399621 B1 KR101399621 B1 KR 101399621B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
mcc
day
diarrhea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087012193A
Other languages
English (en)
Korean (ko)
Other versions
KR20080064177A (ko
Inventor
파멜라 시어스
유에-콩 슈
스타르 루이스 밀러-샹글
로버트 브라이언 왈시
파라 바바카니
유-훙 치우
알렉스 로메로
셔우드 골바츠
토마스 존 루이에
Original Assignee
옵티머 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옵티머 파마슈티칼즈, 인코포레이티드 filed Critical 옵티머 파마슈티칼즈, 인코포레이티드
Publication of KR20080064177A publication Critical patent/KR20080064177A/ko
Application granted granted Critical
Publication of KR101399621B1 publication Critical patent/KR101399621B1/ko
Assigned to 머크 샤프 앤드 돔 코포레이션 reassignment 머크 샤프 앤드 돔 코포레이션 권리의 전부이전등록 Assignors: 옵티머 파마슈티칼즈 엘엘씨
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020087012193A 2005-10-21 2006-10-23 클로스트리듐 디피실리 관련 설사의 치료 방법 Expired - Fee Related KR101399621B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US60/729,135 2005-10-21
US74964105P 2005-12-12 2005-12-12
US60/749,641 2005-12-12
PCT/US2006/041436 WO2007048059A2 (en) 2005-10-21 2006-10-23 Method of treating clostridium difficile-associated diarrhea

Publications (2)

Publication Number Publication Date
KR20080064177A KR20080064177A (ko) 2008-07-08
KR101399621B1 true KR101399621B1 (ko) 2014-06-18

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087012193A Expired - Fee Related KR101399621B1 (ko) 2005-10-21 2006-10-23 클로스트리듐 디피실리 관련 설사의 치료 방법

Country Status (7)

Country Link
EP (1) EP1940417A4 (https=)
JP (1) JP2009512691A (https=)
KR (1) KR101399621B1 (https=)
CN (2) CN101340919B (https=)
AU (1) AU2006304868B2 (https=)
CA (1) CA2626698C (https=)
WO (1) WO2007048059A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
EP3801578B1 (en) * 2018-06-07 2023-08-30 Artugen Therapeutics Ltd. B. amyloliquefaciens strain and therapeutic use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
KR20050053598A (ko) * 2002-07-29 2005-06-08 옵티머 파마슈티칼즈, 인코포레이티드 티아쿠미신 제조법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
ATE516024T1 (de) * 2004-05-14 2011-07-15 Optimer Pharmaceuticals Inc Behandlung von krankheiten im zusammenhang mit der anwendung von antibiotika
JP5166040B2 (ja) * 2005-01-31 2013-03-21 オプティマー ファーマシューティカルズ、インコーポレイテッド １８員大環状化合物及びその類似化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
KR20050053598A (ko) * 2002-07-29 2005-06-08 옵티머 파마슈티칼즈, 인코포레이티드 티아쿠미신 제조법

Also Published As

Publication number Publication date
CA2626698A1 (en) 2007-04-26
CN101340919A (zh) 2009-01-07
CN102503994A (zh) 2012-06-20
KR20080064177A (ko) 2008-07-08
AU2006304868A1 (en) 2007-04-26
CN101340919B (zh) 2011-12-07
HK1126410A1 (en) 2009-09-04
EP1940417A4 (en) 2010-07-07
WO2007048059A3 (en) 2007-05-31
WO2007048059A2 (en) 2007-04-26
JP2009512691A (ja) 2009-03-26
CA2626698C (en) 2015-12-01
AU2006304868B2 (en) 2013-02-21
EP1940417A2 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
Liu et al. Baicalin synergy with β-lactam antibiotics against methicillin-resistant Staphylococcus aureus and other β-lactam-resistant strains of S. aureus
WAISBREN et al. A clinical appraisal of neomycin
Eykyn et al. Metronidazole and anaerobic sepsis.
EP2826473B1 (en) Antibacterial use of patchoulol
US20140107054A1 (en) Method of treating clostridium difficile-associated diarrhea
KR101399621B1 (ko) 클로스트리듐 디피실리 관련 설사의 치료 방법
CN115725446A (zh) 一种抗结直肠肿瘤的屎肠球菌及其应用
US20110319485A1 (en) Composition Having Anti-Helicobacter Pylori Activity And Its Application To Inhibit Helicobacter Pylori
JP2961182B2 (ja) クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US20190307744A1 (en) Pharmaceutical compositions comprising clofazimine analog compound b746 or clofazimine analog compound b826
CN116350628B (zh) Su3327在制备降低多黏菌素细胞毒性和肾毒性的药物中的用途
WO2012050826A1 (en) Methods for treating clostridium difficile infections
Allami et al. Antimicrobial activity of herbal mixture extract combination on microorganisms isolated from urinary tract infection
Stein et al. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens
Bernabe et al. Insoluble polysaccharides produced in plant cell cultures protect from Clostridioides difficile colitis
KR101849424B1 (ko) 발효된 대두 추출물의 프리바이오틱 조성물 제조를 위한 용도
Olusola et al. A comparative study on the effect of Massularia acuminata fractions against bacterial and fungal isolates from the oral cavity
Pan et al. Prevention of the drug resistance of Helicobacter pylori with 8-octyl berberine by increasing membrane permeability and reducing motility
EP1670496B1 (en) A glycopeptide composition with improved antibiotic activity
CN120154605B (zh) 去氢钩藤碱在制备降低多黏菌素毒性药物中的应用
KR101790296B1 (ko) 네트롭신을 유효성분으로 포함하는 그람음성 세균에 대한 폴리믹신의 항균 활성을 증가시키는 조성물
Katara et al. Role of bacteria and fungi in antibiotic production
JP7776069B2 (ja) 高アンモニア血症の治療又は予防用医薬組成物
Vallee et al. Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy.
HK1126410B (en) Method of treating clostridium difficile-associated diarrhea

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170521

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170521